These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Therapy of acute myeloid leukemia: towards a patient-oriented, risk-adapted approach. Mandelli F; Petti MC; Lo Coco F Haematologica; 1998 Nov; 83(11):1015-23. PubMed ID: 9864924 [TBL] [Abstract][Full Text] [Related]
25. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027 [TBL] [Abstract][Full Text] [Related]
26. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754 [TBL] [Abstract][Full Text] [Related]
27. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol. Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387 [TBL] [Abstract][Full Text] [Related]
28. Induction and postremission strategies in acute myeloid leukemia: state of the art and future directions. Rosenblat TL; Jurcic JG Hematol Oncol Clin North Am; 2011 Dec; 25(6):1189-213. PubMed ID: 22093583 [TBL] [Abstract][Full Text] [Related]
29. [Treatment of acute lymphoblastic leukemia in adults with seven-drug induction therapy and intensive consolidation with or without autologous stem cell transplantation followed by maintenance therapy. Experience of a single center]. Doubek M; Mayer J; Korístek Z; Protivánková M; Brychtová Y; Oborilová A; Král Z; Klabusay M; Tomíska M; Buchtová I; Vorlícek J Cas Lek Cesk; 2002 Mar; 141(4):122-6. PubMed ID: 12046256 [TBL] [Abstract][Full Text] [Related]
30. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664 [TBL] [Abstract][Full Text] [Related]
31. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106 [TBL] [Abstract][Full Text] [Related]
32. [Recent progress in the treatment of acute leukemia]. Kimura Y Gan To Kagaku Ryoho; 2003 Jul; 30(7):895-901. PubMed ID: 12894700 [TBL] [Abstract][Full Text] [Related]
33. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia? Song KW; Lipton J Bone Marrow Transplant; 2005 Aug; 36(3):183-91. PubMed ID: 15937497 [TBL] [Abstract][Full Text] [Related]
34. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy. Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J; Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677 [TBL] [Abstract][Full Text] [Related]
35. The role of autologous transplantation for acute myeloid leukemia in first and second remission. Linker C Best Pract Res Clin Haematol; 2007 Mar; 20(1):77-84. PubMed ID: 17336257 [TBL] [Abstract][Full Text] [Related]
36. Timed sequential induction chemotherapy and risk-adapted postremission therapy for acute myelogenous leukemia. Kalaycio M; Advani A; Pohlman B; Sekeres M; Tripp B; Rybicki L; Sobecks R Am J Hematol; 2008 Nov; 83(11):831-4. PubMed ID: 18756545 [TBL] [Abstract][Full Text] [Related]
37. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study. Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987 [TBL] [Abstract][Full Text] [Related]
38. Risk-adapted induction and consolidation therapy in adults with de novo AML aged = 60 years: results of a prospective multicenter trial. Heil G; Krauter J; Raghavachar A; Bergmann L; Hoelzer D; Fiedler W; Lübbert M; Noens L; Schlimok G; Arnold R; Kirchner H; Ganser A Ann Hematol; 2004 Jun; 83(6):336-44. PubMed ID: 15034758 [TBL] [Abstract][Full Text] [Related]
39. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]